---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-060239"
form_type: "8-K"
ticker: "NVCT"
cik: "0001875558"
company_name: "Nuvectis Pharma, Inc."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T01:38:45.026987+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nuvectis Pharma gets FDA clearance to begin Phase 1 trial for NXP900

## Summary
- FDA cleared IND for NXP900, including Phase 1 clinical trial protocol.
- NXP900 is a precision oncology drug; Nuvectis now has two clinical-stage candidates.
- CEO Ron Bentsur: IND clearance is a significant milestone for corporate strategy.
- NXP900 targets cancers with unmet medical need via differentiated mechanism of action.

## SEC filing metadata
- accession: 0001104659-23-060239
- form_type: 8-K
- ticker: NVCT
- cik: 0001875558
- company_name: Nuvectis Pharma, Inc.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1875558/000110465923060239/0001104659-23-060239-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1875558/000110465923060239/tm2315778d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-060239
- JSON: https://secwatch.observer/filing/0001104659-23-060239.json
- Plain text: https://secwatch.observer/filing/0001104659-23-060239.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.